Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition.
暂无分享,去创建一个
J. Ross | Yusu Gu | K. Peterson | L. Mao | R. Clark | M. Hongo | J. Ross | Y. Gu | T. Ryoke | Kirk L. Peterson
[1] JürgenMeyer,et al. Recombinant Growth Hormone Therapy in Patients With Ischemic Cardiomyopathy , 1999 .
[2] J. Ross. Growth hormone, cardiomyocyte contractile reserve, and heart failure. , 1999, Circulation.
[3] T. Voigtländer,et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. , 1999, Circulation.
[4] L. Saccá,et al. Growth Hormone and the Heart , 1999, Mineral and Electrolyte Metabolism.
[5] J. Ross,et al. Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. , 1998, Journal of cardiac failure.
[6] M. Friedrich,et al. Randomized, double-blind, placebo-controlled trial of growth hormone in patients with dilated cardiomyopathy , 1998 .
[7] P. Poole‐Wilson,et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy , 1998, The Lancet.
[8] M. Yano,et al. Growth hormone enhances cardiac performance and sarcoplasmic reticulum Ca2+releasing channels (ryanodine receptors) in cardiomyopathic hamsters , 1998 .
[9] Y. Murakami,et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Ross,et al. Force-frequency effect is a powerful determinant of myocardial contractility in the mouse. , 1997, The American journal of physiology.
[11] Y. Hayashizaki,et al. Identification of the Syrian hamster cardiomyopathy gene. , 1997, Human Molecular Genetics.
[12] J. Ross,et al. Transthoracic echocardiography in models of cardiac disease in the mouse. , 1996, Circulation.
[13] J. Ross,et al. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. , 1996, Circulation.
[14] E. Bove,et al. Collagen content in normal, pressure, and pressure-volume overloaded developing human hearts. , 1996, The American journal of cardiology.
[15] B. Biondi,et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.
[16] J. Mayer,et al. Ten-year institutional experience with palliative surgery for hypoplastic left heart syndrome. Risk factors related to stage I mortality. , 1995, Circulation.
[17] RenhuiYang,et al. Growth Hormone Improves Cardiac Performance in Experimental Heart Failure , 1995 .
[18] R. Ross,et al. Acquired growth hormone resistance. , 1995, European journal of endocrinology.
[19] S. Coughlin,et al. Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.
[20] V. Fuster,et al. Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.
[21] C. Carella,et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. , 1993, The Journal of clinical endocrinology and metabolism.
[22] J. Keiser,et al. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates. , 1991, Circulation research.
[23] E. B. Pedersen,et al. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. , 1991, The Journal of clinical endocrinology and metabolism.
[24] A. Weissberger,et al. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. , 1990, Metabolism: clinical and experimental.
[25] B. Sherman,et al. Variability in the quantitation of circulating growth hormone using commercial immunoassays. , 1989, The Journal of clinical endocrinology and metabolism.
[26] M. Fishbein,et al. Cardiac architectural changes with hypertrophy induced by excess growth hormone in rats. , 1988, Laboratory investigation; a journal of technical methods and pathology.
[27] W. Little,et al. The Left Ventricular dP/dtmax‐End‐Diastolic Volume Relation in Closed‐Chest Dogs , 1985, Circulation research.
[28] E. G. Hunter,et al. Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. , 1984, Canadian journal of physiology and pharmacology.
[29] E. Froesch,et al. Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. , 1981, The Journal of clinical investigation.
[30] J. Ross,et al. Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. , 1976, Progress in cardiovascular diseases.
[31] W Grossman,et al. Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.
[32] E. Bajusz. Hereditary cardiomyopathy: a new disease model. , 1969, American heart journal.